Bristol Myers Squibb (BMS), a prominent player in oncology, has recently announced significant advancements to its longstanding initiative, Standing in the Gaap. This program aims to address the ongoing disparities in care for individuals affected by multiple myeloma (MM), particularly in underserved communities. As the initiative celebrates its tenth anniversary, BMS is intensifying its commitment to ensuring that patients have equitable access to education, resources, and community-oriented solutions.
A Decade of Commitment
Since its inception, Standing in the Gaap has focused on understanding and addressing the barriers that many patients face in receiving adequate multiple myeloma care. The program has made strides over the past decade by facilitating over 50 educational events and reaching more than 5,000 participants. Additionally, it has fostered a robust digital community of nearly 60,000 individuals, enhancing awareness and engagement in the multiple myeloma landscape.
Launching a Pioneering Survey
At the heart of the program’s evolution is the introduction of one of the largest surveys ever conducted in the United States regarding multiple myeloma. This survey aims to capture insights into the factors contributing to care gaps, providing a comprehensive understanding of the patient experience. By engaging over 1,000 patients, caregivers, and healthcare providers, BMS is prioritizing the voices of those who face persistent barriers to care.
Collaborating with Advocacy Organizations
To ensure that the survey reflects genuine community concerns, BMS collaborated with several leading patient advocacy organizations, including the International Myeloma Foundation and the Multiple Myeloma Research Foundation. This collaborative effort underscores the program’s commitment to real-world experience and community needs.
A Listening-Led Approach
Andrew Whitehead, BMS’s vice president and head of population health, emphasized the importance of representation in research and access to care. He noted, “Even the most advanced treatments can fall short if patients aren’t represented in research.” This philosophy is central to the Standing in the Gaap initiative, which seeks to overcome the systemic challenges that patients encounter in their healthcare journeys.
Broadening the Scope of Care
Originally created to address the specific challenges faced by African Americans with multiple myeloma, the program is now evolving to encompass a wider array of populations. This shift reinforces BMS’s dedication to culturally responsive, community-informed approaches in the realm of multiple myeloma care. By expanding its focus, BMS aims to ensure that more patients receive the support and resources they need.
Translating Insights into Action
Dr. Joseph Mikhael, chief medical officer of the International Myeloma Foundation, highlighted the significance of listening to patients and care partners. He stated, “Efforts like this create an opportunity to translate lived experience into meaningful action.” By gathering insights through the survey, BMS intends to identify where support is lacking and to take focused action that will make a tangible difference in the lives of those affected by multiple myeloma.
Future Directions
The insights gained from the Standing in the Gaap survey will not only inform BMS’s future programming but will also guide partnerships and engagement strategies within the multiple myeloma community. This proactive approach is essential for addressing the evolving needs of patients and caregivers alike.
Bristol Myers Squibb remains steadfast in its mission to discover and deliver innovative medicines for serious diseases. The company continues to push the boundaries of science to redefine what is possible in medicine, always with a patient-centric focus.
Key Takeaways
- Bristol Myers Squibb is evolving its Standing in the Gaap program to enhance equitable care for multiple myeloma patients.
- A major survey will gather insights from over 1,000 patients, caregivers, and providers to address care gaps.
-
Collaboration with advocacy organizations ensures that the program reflects real-world experiences and community needs.
-
The initiative is expanding its focus to include a more diverse range of populations affected by multiple myeloma.
-
Insights from the survey will guide future programming and partnerships, enhancing support for those impacted by the disease.
In conclusion, Bristol Myers Squibb’s commitment to refining the Standing in the Gaap initiative exemplifies a forward-thinking approach to healthcare equity. By listening to the community and actively addressing care disparities, BMS is setting a new standard for patient engagement and support in the field of multiple myeloma.
Read more → www.pharmabiz.com